A multicenter, randomized, double-blind, placebo-controlled study evaluating the effect of inclisiran in the prevention of major adverse cardiovascular events in high-risk patients in primary prevention (VICTORION-1 PRE
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Phase: III
- Execution start: 16/05/2023
- End of execution: 30/04/2029
- PI: JUAN DIEGO MEDIAVILLA GARCIA
